Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rifamycin SV-MMX in Acute Uncomplicated Diverticulitis
NCT01847664Phase 2Completed
- Sponsor
- Dr. Falk Pharma GmbH
- Start
- Aug 2013
- Primary completion
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of rifamycin SV-MMX in acute diverticulitis (AD) (3 arms), sponsored by Dr. Falk Pharma GmbH. Primary endpoint: Rate of patients with treatment success at the day 10 visit. Started Aug 2013; status: completed.
02
Drugs
rifamycin SV-MMX
03
Conditions
acute diverticulitis (AD)
Beyond the preview
Go deeper on NCT01847664.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01847664.